Onconetix Inc
onconetix.comWhat Do They Do?
Sells Proclarix, a blood-based prostate cancer test, to laboratories, hospitals and medical centers.
10-K for FY2025, filed Mar 13, 2026We are a commercial stage biotechnology company focused on the research, development, and commercialization of innovative solutions for…View ↗
Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular…View ↗
The Company derives revenue through sales of its products, which includes Proclarix, its diagnostic product, directly to end users…View ↗
How Do They Make Money?
Customers buy diagnostic products, with the sale completed when the product is transferred to them. The company bills life-sciences customers for testing and assay-development work as projects proceed, and receives license payments when rights are transferred, with royalties tied to later product sales.
10-K for FY2025, filed Mar 13, 2026Proteomedix provides a range of services to life sciences customers referred to as “Development Services” including testing for biomarker…View ↗
The Company derives revenue through sales of its products, which includes Proclarix, its diagnostic product, directly to end users…View ↗
The Company generates other revenue including license revenue through agreements that grant third parties rights to use its intellectual…View ↗
$815.4K
-
10-K for FY2025, filed Mar 13, 2026
$815.4K ↗
Who Are Their Customers?
Proclarix is sold directly to laboratories, hospitals and medical centers, and also through distributors. The company describes pursuing collaboration access to integrated diagnostic systems and using commercial laboratory networks to reach physicians.
10-K for FY2025, filed Mar 13, 2026The Company derives revenue through sales of its products, which includes Proclarix, its diagnostic product, directly to end users…View ↗
In clinical diagnostics high throughput assay parameters like PSA typically are performed on closed, fully integrated systems that use…View ↗
Lower volume parameters are run on smaller, open systems that are used in laboratories for tests with lower throughput to complement the…View ↗
General practitioners recruit patients for screening and decide whether to refer a patient to a specialist. They have an important…View ↗
Do Revenues Turn Into Profits?
No. It lost $14M in FY2025.
10-K for FY2025, filed Mar 13, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$2.9MView ↗
- ▲ +21% (Loss)
- vs −$2.4M in Q2 FY2025
-
Sep 11, 2026
Onconetix agreed to lend up to $5.0 million to acquisition target Realbotix
It advanced $2.5 million; the note will be canceled if the pending share exchange closes.
Sources
8-K, filed Sep 14, 2026
On September 11, 2026, Onconetix, Inc. (the “Company”) entered into a Grid Promissory Note (the “Note”) with Realbotix, LLC (“Realbotix”)…View ↗
-
Apr 24, 2026
Sammy Dorf became chairman after Andrew Oakley resigned
Sources
8-K, filed Apr 24, 2026
Effective on April 20, 2026, Andrew Oakley and Thomas Meier notified the Board of Directors (the “Board”) of Onconetix, Inc, a Delaware…View ↗
-
Mar 24, 2026
David White was appointed chief executive officer
Sources
8-K, filed Mar 24, 2026
On March 18, 2026, the Board of Directors (the “Board”) of Onconetix, Inc, a Delaware corporation (the “Company”) appointed David White as…View ↗
Vaccines to prostate diagnostics
The older report described a vaccine research and development business with licensed vaccine candidates and potential licensing partners. The latest report centers on commercializing Proclarix, a blood test for prostate cancer.
10-K for FY2022, filed Mar 9, 2023
Who Do They Compete With?
Competes with Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, OPKO Health, Cleveland Diagnostics, Gen-Probe, Hologic, MdxHealth, Exosome Diagnostics, Bio-Techne, and A3P Biomedical
10-K for FY2025, filed Mar 13, 2026There are a number of tests already on the market or in clinical testing or commercial development that are also intended to triage…View ↗
Loading...
